Home › Compare › BKCYF vs ABBV
BKCYF yields 7.19% · ABBV yields 3.06%● Live data
📍 BKCYF pulled ahead of the other in Year 1
Combined, BKCYF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BKCYF + ABBV for your $10,000?
Bank of Cyprus Holdings Public Limited Company, through its subsidiaries, provides banking, financial, and insurance services. It offers current, savings, notice, instant access, and fixed deposits; housing, student, consumer, business and business premises, term, and home or investment loans; and asset finance, factoring, trade facilities, European financial, project finance, shipping finance, and syndicated and corporate lending services, as well as hire purchase services for car and equipment. The company also provides debit, credit, prepaid, and special cards; reward programs; digital products; digital banking, and payments and services; motor, home, business, life, create capital, and health insurance products; SME guarantee facility services; day to day banking services; investment banking and brokerage, asset and wealth management, market execution and hedging, and structured and funding solutions; investment products and services; and custody and depositary services. In addition, it is involved in the property trading and development activities; land development and operation of a golf resort; management administration and safekeeping of UCITS units; administration of guarantees and holding of real estate properties; collection of the existing portfolio of receivables, including third party collections; and provision of card processing transaction, auction, and secretarial services. As of June 30, 2022, the company operated 86 branches in Cyprus. Bank of Cyprus Holdings Public Limited Company was founded in 1899 and is headquartered in Nicosia, Cyprus.
Full BKCYF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.